kabutan

Astellas Pharma, 3% Increase in Net Income, Update Record High for Second Consecutive Term, Dividend Raised by 2 Yen

Mon Apr 27, 2026 3:30 pm JST Earnings

4503 Astellas Pharma Inc. 【IFRS】

Earnings Report

Astellas Pharma Inc. <4503> [TSE Prime] announced its financial results (based on IFRS) after the market closed on April 27th (15:30). The consolidated net income for the fiscal year ended March 2026 surged by 5.7 times that of the previous term, reaching 291 billion yen, exceeding the previous forecast of 250 billion yen. For the fiscal year ending March 2027, the consolidated net income is expected to grow by 2.9% to 300 billion yen, marking the second consecutive term of record-high profits. This will be the sixth consecutive term of revenue and the third consecutive term of profit growth.

At the same time, the company has decided to increase the dividend this fiscal year to 80 yen, an increase of 2 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated net income dropped to 43.5 billion yen, a 41.9% decrease compared to the same period last year. The operating profit margin significantly dropped from 13.8% in the same period last year to 9.1%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 1,603,672 25,518 24,969 17,045 9.5 70 Apr 25, 2024 IFRS
Mar, 2025 1,912,323 41,039 31,237 50,747 28.4 74 Apr 25, 2025 IFRS
Mar, 2026 2,139,245 382,633 376,587 291,535 162.8 78 Apr 27, 2026 IFRS
YoY +11.9% +832.4% +1,105.6% +474.5% +474.1%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Guidance 2,100,000 340,000 330,000 250,000 139.6 78 Feb 4, 2026 IFRS
Mar, 2026 Results 2,139,245 382,633 376,587 291,535 162.8 78 Apr 27, 2026 IFRS
Revision Rate +1.9% +12.5% +14.1% +16.6% +16.6%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 1,030,114 199,378 194,606 147,635 82.4 39 Oct 30, 2025 IFRS
Apr - Sep, 2026 Guidance ー ー ー ー － 40 Apr 27, 2026 IFRS
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 1,912,323 41,039 31,237 50,747 28.4 74 Apr 25, 2025 IFRS
Mar, 2026 2,139,245 382,633 376,587 291,535 162.8 78 Apr 27, 2026 IFRS
Mar, 2027 Guidance 2,220,000 395,000 385,000 300,000 167.5 80 Apr 27, 2026 IFRS
YoY +3.8% +3.2% +2.2% +2.9% +2.9%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2025 459,294 63,520 60,554 74,896 41.8 13.8 Apr 25, 2025 IFRS
Apr - Jun, 2025 505,794 94,647 90,416 68,422 38.2 18.7 Jul 30, 2025 IFRS
Jul - Sep, 2025 524,320 104,731 104,190 79,213 44.2 20.0 Oct 30, 2025 IFRS
Oct - Dec, 2025 571,206 134,502 133,957 100,379 56.1 23.5 Feb 4, 2026 IFRS
Jan - Mar, 2026 537,925 48,753 48,024 43,521 24.3 9.1 Apr 27, 2026 IFRS
YoY +17.1% -23.2% -20.7% -41.9% -41.9%

Related Articles